Mark-10 Introduces New Integrated Controls to Streamline Essential Force Measurement

Mark-10 introduces the Series F family of force testers for quality control and process monitoring in fabrication and assembly operations. The Series F family integrates IntelliMESUR software for machine control, force measurement, and data acquisition in a single clean graphical user interface. This brings another level of efficiency into recurrent testing, allowing users to define and store test sequences for both routine and unique tasks, store all measurements, and perform standard and specialized data analysis.

Mark-10 force and torque measuring instruments have long enjoyed a reputation for precision engineering and reliable operation in challenging environments. The new degree of operational simplicity in Series F force testers offers decreased test times for both routine and unique procedures to validate medical device manufacturing, measure packaging performance, confirm plastics formulation, check automotive module consistency, and verify aerospace component fabrication.

For example, medical syringe manufacturers must verify the syringe plunger force is within limits. The requirements vary with syringe geometry, so the test parameters must be adjusted for each different design. The Series F allows the full test procedure to be stored for each distinct geometry, and also allows the measured results to be correlated with syringe configuration, the plastic composition of the components, or any other elements that could influence syringe performance.

The same ease of operation and powerful data analysis can be applied to such applications as automobile seatbelt retraction force testing, package opening force verification for medication or consumer goods, and tension and compression measurements for plastic or metal test coupons for aerospace applications.

Mark Fridman, President of Mark-10, notes that the new Series F + IntelliMESUR allows more complex test sequences to be performed, without introducing more complexity for operators. “It’s more configurable, but is also easy to use. We anticipate our customers will see significant reductions in test time and cost, while having data analysis capabilities that bring added value to test operations.”

More information on the Series F + IntelliMESUR family is available at https://mark-10.com/seriesf/.

 

SourceMark-10

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”